Intercell AG

euro adhoc: Intercell AG
Annual Reports
Intercell presents 2006 Annual Report

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

annual report

27.04.2007

Following a successful year, Intercell AG (VSE, "ICLL") today presents its Annual Report 2006.

The illustrated Annual Report contains the audited consolidated financial statements according to IFRS and gives detailed information on Intercell’s latest achievements and anticipated milestones. It highlights the company’s progress in product development and the scientific and commercial potential of its technology platforms. At the same time, Intercell AG publishes its statutory financial report according to Austrian GAAP.

The online version of the Annual Report is now available for download at www.intercell.com. A hard copy can be requested at Intercell’s Communication Department by mail(communications@intercell.com) or by phone (+43-1-20620-0).

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the design and Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms, and has in-house GMP manufacturing capability. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck&Co., Wyeth, sanofi pasteur, Kirin and the Statens Serum Institut. The Company’s leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006. The regulatory process towards a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) has been initiated. The broad development pipeline includes a Pseudomonas vaccine in Phase II, a therapeutic vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and S.aureus which are in Phase I, and five products focused on infectious diseases in preclinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

@@start.t2@@end of announcement                                                 euro adhoc 27.04.2007 08:13:24
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: